SCHEMBL24650661

SCHEMBL24650661

Nc1ncnc2c1c(I)cn2C1CNC1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MTOR P42345 1/20 0.55
RAB9A P51151 1/20 0.55
ADK P55263 11/20 0.54
SRC P12931 5/20 0.51
EGFR P00533 3/20 0.51
ABL1 P00519 3/20 0.49
ABL2 P42684 2/20 0.49
HASPIN Q8TF76 1/20 0.48
IGF1R P08069 2/20 0.47
DAPK3 O43293 1/20 0.46
MAP4K4 O95819 1/20 0.46
PAK4 O96013 1/20 0.46
LCK P06239 1/20 0.46
FYN P06241 1/20 0.46
CSF1R P07333 1/20 0.46
RET P07949 1/20 0.46
FGFR1 P11362 1/20 0.46
PRKACA P17612 1/20 0.46
FLT1 P17948 1/20 0.46
LTK P29376 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29999095 1.00 MTOR (0.55) MTORRAB9AADKSRCEGFR
SCHEMBL27088114 0.89 SRC (0.65) MTORRAB9AADKSRCEGFR
SCHEMBL29999242 0.89 SRC (0.65) MTORRAB9AADKSRCEGFR
SCHEMBL24251862 0.89 SRC (0.65) MTORRAB9AADKSRCEGFR
SCHEMBL30767877 0.87 SRC (0.57) MTORRAB9AADKSRCEGFR
SCHEMBL16237288 0.86 SRC (0.59) MTORRAB9AADKSRCEGFR
SCHEMBL19743649 0.86 FGR (0.57) MTORRAB9AADKSRCEGFR
Hydrochloric Acid SCHEMBL29999025 0.85 FGR (0.56) MTORRAB9AADKSRCEGFR
SCHEMBL400626 0.84 SRC (0.61) MTORRAB9AADKSRCEGFR
SCHEMBL30155310 0.84 ABL1 (0.64) MTORRAB9AADKSRCEGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240382488-A1 NEK7 INHIBITORS Halia Therapeutics, Inc. 2024-11-21 US disclosed
US-20240317758-A1 NEK7 INHIBITORS Halia Therapeutics, Inc. 2024-09-26 US disclosed
CN-117597346-A NEK7 inhibitors 哈利亚治疗公司 2024-02-23 CN disclosed
EP-4320127-A1 NEK7 INHIBITORS Halia Therapeutics, Inc. (US) 2024-02-14 EP disclosed
WO-2022216680-A1 NEK7 INHIBITORS Halia Therapeutics, Inc. (US) 2022-10-13 WO disclosed
WO-2022212326-A1 NEK7 INHIBITORS Halia Therapeutics, Inc. (US) 2022-10-06 WO disclosed
WO-2022212326-A1 NEK7 INHIBITORS Halia Therapeutics, Inc. (US) 2022-10-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240382488-A1 NEK7 INHIBITORS NEK7, NEK11, NEK2 MTOR 2067/4885RAB9A 1120/4885ADK 168/4885
US-20240317758-A1 NEK7 INHIBITORS NEK7, NEK5, NEK1 MTOR 1341/4885RAB9A 3236/4885ADK 157/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.